

Creative Diagnostics Introduces New ELISA Kits to Accelerate Autoimmunity Research

Creative Diagnostics has announced a series of new ELISA Kits to assist researchers in studying the mechanisms of autoimmunity.

NEW YORK CITY, NEW YORK, UNITED STATES, August 26, 2023 /EINPresswire.com/ -- [Creative Diagnostics](#), a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced a series of new ELISA Kits to assist researchers in studying the mechanisms of [autoimmunity](#), including those associated with anti-neutrophil, anti-nuclear, rheumatic diseases, endocrine autoantibodies, and the neurological system.

The immune system has very powerful effector mechanisms to destroy a wide range of pathogens. Early in the study of immunity, it was recognized that if these mechanisms were detrimental to the host, severe tissue damage could result. The autoimmune response is similar to the normal immune response to pathogens in that it is specifically activated by antigens (in this case, self-antigens or autoantigens) and produces auto-reactive effector cells and antibodies (called autoantibodies) against the self-antigens. If the response to one's own tissues is not properly regulated, it can lead to a variety of chronic syndromes known as autoimmune diseases.

Autoimmune diseases comprise more than 70 different disorders and affect approximately 5% of the population in Western countries. In human autoimmune diseases, a large number of serum antibodies can be detected against functional cellular structures (nucleic acids, nuclear molecules, receptors, or other functional cellular components), and the presence of such antibodies is central to the diagnosis and classification of these diseases. In addition, several longitudinal cohort studies have shown that patients may carry autoantibodies many years before the onset of clinical symptoms, and the detection of these antibodies in serum has been shown to have a strong predictive value.

Autoimmune diseases are among the most challenging scientific and clinical problems in immunology. The understanding of the pathogenic mechanisms is still incomplete and theories and hypotheses still outnumber facts. The application of new technologies and the rapid improvement in the understanding of auto tolerance will bring clearer and more definitive answers to the mystery of autoimmune diseases.

To accelerate the study of autoimmune diseases, Creative Diagnostics now offers a series of

autoimmune ELISA kits to biopharmaceutical research organizations and laboratories. The kits are designed to detect a wide range of autoantibodies, including those associated with anti-neutrophil, anti-nuclear, rheumatic diseases, endocrine autoantibodies, and the neurological system.

For example, the Human Myeloperoxidase IgG ELISA Kit (Catalog # DEIA1698) is intended for the qualitative and semi-quantitative detection of IgG class antibodies to myeloperoxidase in human serum. The test system is designed to be used as an aid in the diagnosis of various autoimmune vasculitic diseases characterized by elevated levels of antineutrophil cytoplasmic antibodies (ANCA). MPO-ANCA may be associated with autoimmune diseases such as Wegener's granulomatosis, ICGN, MPA, and PRS.

These autoimmune ELISA kits from Creative Diagnostics are available now. To learn more, please visit <https://www.creative-diagnostics.com/autoimmune-elisa-kits.htm>.

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers' assay development and manufacturing needs.

Thomas Schmitt

Creative Diagnostics

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/652071451>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.